2017 » Johns Hopkins Drug Discovery
1672
page,page-id-1672,page-child,parent-pageid-21,page-template-default,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

2017

113. Nedelcovych M, Dash RP, Tenora L, Zimmermann SC, Gadiano AJ, Garrett C, Alt J, Hollinger KR, Pommier E, Jancarik A, Rojas C, Thomas AG, Wu Y, Wozniak K, Majer P, Slusher BS, Rais R. “Enhanced Brain Delivery of (2-(phosphonomethyl)pentanedioic acid) following Intranasal Administration of its y-substituted Ester Prodrugs.”  Mol Pharm. 2017 epub ahead of print [PubMed]

 

112. Nedelcovych MT, Tenora L, Kim BH, Kelschenbach J, Chao W, Hadas E, Jancarik A, Prchalova E, Zimmermann SC, Dash RP, Gadiano AJ, Garrett C, Furtmuller G, Oh B, Brandacher G, Alt J, Majer P, Volsky DJ, Rais R, Slusher BS. “N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-L-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.”  J Med Chem. 2017, Jul 31, epub ahead of print  [PubMed]

 

111. Rais R, Vavra J, Tichy T, Dash RP, Gadiano AJ, Tenora L, Monincova L, Barinka C, Alt J, Zimmermann SC, Slusher CE, Wu Y, Wozniak K, Majer P, Tsukamoto T, Slusher BS. “Discovery of a para-acetoxy-benzyl ester prodrug of a hydroxamate-based Glutamate Carboxypeptidase II inhibitor as oral therapy for neuropathic pain.” J Med Chem, 2017, Jul 31, epub ahead of print [PubMed]

 

110. Nedelcovych M, Manning AA, Semenova S, Gamaldo C, Haughey NJ, Slusher BS. “The Psychiatric Impact of HIV.” ACS Chemical Neuroscience, 2017, Jul 19;8(7):1432-1434  [PubMed]

 

109. Baxter VK, Glowinski R, Braxton AM, Potter MC, Slusher BS, Griffin DE. “Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis.” Virology, 2017, 508, 134-149 [PubMed]

 

108. Benbow SJ, Wozniak KM, Kulesh B, Savage A, Slusher BS, Littlefield BA, Jordan MA, Wilson L, Feinstein SC.  “Microtubule Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy Induced Peripheral Neuropathy.”  J Neurotox Res., 2017 Apr 8 9729-6 [PubMed]

 

107. Gamo NJ, Birknow MR, Sullivan D, Kondo MA, Horiuchi Y, Sakurai T, Slusher BS, Sawa A.  “Valley of death: A proposal to build a “translational bridge” for the next generation.” Neuroscience Research, 2017, 115, 1-4 [PubMed]

 

106. Kremer JC, Prudner BC, Lange SE, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA.  “Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers.”  Cell Rep. 2017, Jan 24; 18(4):991-1004  [PubMed]

 

105.  Figuera-Losada M, Thomas AG, Stathis M, Stockwell BR, Rojas C, Slusher BS.  “Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs.” Biochemistry and Biophysics Reports, 2017, Vol 9, Pages 266-272

 

104.  Yokley BH, Hartman M, Slusher BS.  “Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.”  ACS Chemical Neuroscience, 2017,Mar 15;8(3):429-431  [PubMed]

 

103.  Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM.  “Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.”  J Control Release, 2017, Jan 31, [PubMed]

lowgo_bottom